Diabetes Self-Management Blog

For more than three years, the Type 2 diabetes drug rosiglitazone (brand name Avandia) has been the subject of continually bad news, beginning with the 2007 study that found the drug associated with a 43% higher risk of heart attack. Lately, however, it seemed like the luck of Avandia’s manufacturer, GlaxoSmithKline (GSK), might change, or at least not get any worse. As we reported in May, GSK initiated a massive study comparing Avandia with its main competitor, pioglitazone (Actos), aiming to enroll 16,000 people over five years. The company hoped that this trial, which was mandated by the US Food and Drug Administration (FDA), would conclusively support its position that Avandia is safe. Then in July, an official FDA panel voted to keep Avandia on the market. It seemed like until 2015, Avandia might get a break in the headlines.

But hardly a week later, the FDA ordered a halt to new enrollment in the ongoing trial of Avandia and Actos, telling GSK to inform researchers, review boards, and ethics committees involved in the trial to review the safety findings and votes of the previous week’s meetings. This information could be used to update informed-consent forms for both current and, if the FDA allows enrollment to resume, future trial participants.

Now, there is more bad news for the drug, this time from across the pond. Last week, Britain’s Medicines and Healthcare Products Regulatory Agency announced that an official panel of independent experts had voted to recommend Avandia’s removal from the UK market. According to an Associated Press article, the panel uncovered no new evidence but simply decided that the risks of Avandia outweighed its benefits. It also revealed that it had sent doctors a letter in July “advising them to consider alternative treatments.” Furthermore, BMJ — Britain’s most prominent medical journal — called for Avandia to be withdrawn immediately and said it never should have been approved, asserting that GSK had behaved badly throughout the regulatory process in the face of problematic data. GSK countered that it had always behaved appropriately and had conducted extensive research on the drug. This news comes just as the European Medicines Agency — which makes recommendations that all European Union member nations generally follow — has begun meetings to reconsider the status of Avandia. It is possible, therefore, that the drug will soon face new restrictions or withdrawal in all of Europe.

How should the FDA respond to these developments, if at all? Should the United States give consideration to drug regulatory decisions in other countries — in this case, the home country of the drug’s manufacturer? Would you feel comfortable taking a drug that had been banned in Europe? Leave a comment below!

POST A COMMENT       
  

Comments
  1. The FDA should make its own decision based on the facts.

    Posted by Donna C |
  2. Europe often has very good reasons to consider banning a drug. I would hesitate to take a drug that has been banned in Europe.

    I know that the FDA will look at facts and make a decision. But I know what Avandia did to my health in more than one area and I will never take it again. Ditto with Actos. Evidently some people can tolerate the drugs. Butfor how long before they run into severe problems? I had enough sense to get off Avandia - barely in time.

    Posted by Carolyn Koenig |
  3. I took Avandia for a couple of years. Asked my doctor about quitting it. He poo-poo-ed the rumors. I had a heart attack in 2007. I quit the drug, much to his dismay. It is now 2010 and I am still alive, no thanks to Avandia.

    Posted by Charlene Sydow |
  4. 1) Britain has different ways of assessing value than we: Costs vs. Life Years added. We assess on a person-by-person basis, caring less about price, more about benefits. (How much is your life worth? You say, an infinite amount. Britain says, $49,000 a year.) So, if Britain admits they have no more facts than we do, let’s roundly ignore them.
    2) I don’t believe in banning ANY medications. It’s best for doctors to have access to many, many options. Why take an arrow out of their quiver? There will always be SOME people who Avandia would be recommended for.
    Many docs will choose stupidly? Yup. That’s why you need to choose a doctor very carefully…

    Personally, I was on Actos (& Metformin), & got off it as soon as I lost some weight, & my A1c’s have stayed the same with Metformin alone.

    Posted by Yisroel |

Post a Comment

Note: All comments are moderated and there may be a delay in the publication of your comment. Please be on-topic and appropriate. Do not disclose personal information. Be respectful of other posters. Only post information that is correct and true to your knowledge. When referencing information that is not based on personal experience, please provide links to your sources. All commenters are considered to be nonmedical professionals unless explicitly stated otherwise. Promotion of your own or someone else's business or competing site is not allowed: Sharing links to sites that are relevant to the topic at hand is permitted, but advertising is not. Once submitted, comments cannot be modified or deleted by their authors. Comments that don't follow the guidelines above may be deleted without warning. Such actions are at the sole discretion of DiabetesSelfManagement.com. Comments are moderated Monday through Friday by the editors of DiabetesSelfManagement.com. The moderators are employees of R.A. Rapaport Publishing, Inc., and do not report any conflicts of interest. A privacy policy setting forth our policies regarding the collection, use, and disclosure of certain information relating to you and your use of this Web site can be found here. For more information, please read our Terms and Conditions.


Flashpoints
Doctor Payments Revealed (04/16/14)
The Costs of Innovation (04/09/14)
Diabetes to Go (04/02/14)
Veggie Persuasion (03/26/14)

 

 

Disclaimer of Medical Advice: You understand that the blog posts and comments to such blog posts (whether posted by us, our agents or bloggers, or by users) do not constitute medical advice or recommendation of any kind, and you should not rely on any information contained in such posts or comments to replace consultations with your qualified health care professionals to meet your individual needs. The opinions and other information contained in the blog posts and comments do not reflect the opinions or positions of the Site Proprietor.


Carbohydrate Restriction: An Option for Diabetes Management
Some people find that decreasing the amount of carbohydrate they eat can help with blood glucose control. Here’s what to know about this approach.

Insulin Patch Pumps: A New Tool for Type 2
Patch pumps are simpler to operate than traditional insulin pumps and may be a good option for some people with Type 2 diabetes who need insulin.

How Much Do You Know About Vitamins?
Learn what these micronutrients can and can’t do for you.

Complete table of contents
Get a FREE ISSUE
Subscription questions